Fineline Cube

Follow:
14691 Articles
CompanyDrug

Simcere’s Culevibart Wins NMPA Approval as China’s RSV Prevention Monoclonal Antibody Yingmule

GenScript Proposes ProBio Spin-Off for Standalone Listing on HKEX Main Board
CompanyDeals

GenScript Proposes ProBio Spin-Off for Standalone Listing on HKEX Main Board

CompanyDrug

Sino Biopharmaceutical’s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors

CompanyDrug

Fosun Pharma’s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently
CompanyDeals

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

CompanyDrug

Hengrui’s drotokibart BLA Accepted by NMPA for Moderate-to-Severe Atopic Dermatitis

CompanyDrug

GanLee’s GZC8072 Wins NMPA IND Approval for Once‑Weekly Oral Type 2 Diabetes Candidate

Policy / Regulatory

NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three‑Agency Regulatory Adjustment

CompanyDeals

NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline

Policy / Regulatory

NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non‑Oral Dosage Forms

CompanyDrug

Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties
CompanyDeals

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties